R & D

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy

This information is intended to notify the press release issued on January 4 by Bristol Myers Squibb. Please click https://www.bms.com/media/press-releases.html for the original press release.